Shares of Biohaven Pharmaceutical Holding Co. Ltd. (BHVN) are up 14% year-to-date compared to 4% gain by the iShares NASDAQ Biotechnology Index (ETF)(IBB).
Biohaven is a clinical-stage biopharmaceutical company developing drugs for neurological diseases, including rare disorders.
The Company's lead drug candidate is Rimegepant (BHV-3000) for acute treatment of Migraine, which is under phase III development.
Rimegepant belongs to a class of drugs known as CGRP (calcitonin gene-related peptide) receptor antagonist. In clinical studies, CGRP receptor antagonists have been found to be effective as Triptans in the acute treatment of migraines, sans the cardiovascular effects.
The Company initiated two pivotal phase III trials of orally-dosed 75 mg Rimegepant for the acute treatment of migraine last July. The two trials have together enrolled approximately 3,000 subjects, and top line results from both the studies are expected in the first quarter of 2018.
A long term phase II/III safety trial of Rimegepant in patients with migraine was initiated last August. This study, designed to enroll roughly 2,000 patients in the U.S., has so far enrolled more than 1,000 patients. The Company expects enrollment to be completed by the end of the first half of 2018, with top line data scheduled for the fourth quarter of this year.
Another CGRP receptor antagonist, which the Company is developing, is BHV-3500 for the acute treatment and prevention of migraine. An investigational new drug application for BHV-3500 is expected to be submitted to the FDA in first half of 2018.
Also in the pipeline are:
-- Trigriluzole, a novel third-generation prodrug glutamate modulator, under a phase II/III clinical trial in patients with Obsessive-Compulsive Disorder, or OCD.
OCD, which affects 1-2% of the U.S. population, is a chronic and long-lasting disorder in which a person has uncontrollable, reoccurring thoughts (obsessions) and behaviors (compulsions) that he or she feels the urge to repeat over and over.
The phase II/III clinical trial of Trigriluzole is designed to enroll 226 OCD patients across approximately 35 sites in the United States.
-- Trigriluzole is also being explored in the indication of Spinocerebellar Ataxia, a rare inherited neurological disorder.
The topline results from a phase 2/3 clinical trial reported last October revealed that Trigriluzole did not differentiate from placebo on the primary endpoint or key secondary outcome measure at the end of the 8-week randomization phase in patients with spinocerebellar ataxia. However, Biohaven is continuing a long-term (48-week) extension study of Trigriluzole in this indication. The extension study is fully enrolled, and top line results are expected in the fourth quarter of 2018.
-- BHV-0223, an innovative sublingual formulation of Riluzole, as a potential treatment for patients with Amyotrophic Lateral Sclerosis, has successfully completed a bioequivalence study.
Riluzole, marketed as Rilutek and Teglutik, is currently the standard of care treatment for patients with Amyotrophic Lateral Sclerosis.
-- BHV-5000, which is being developed as a potential treatment for neuropsychiatric disorders such as Rett syndrome. The clinical development of BHV-5000 was initiated as recently as January of this year.
Only a little over 3 weeks left for this month to end, and as the Company gears up for an important catalyst, it's time to keep an eye on Biohaven.
Shares of Biohaven have thus far hit a low of $17.00 and a high of $39.51. The Company went public on the New York Stock Exchange on May 4, 2017, offering its shares at a price of $17 each, raising nearly $194 million. Biohaven's IPO represented the largest biopharma IPO on NYSE in over 2 years and third largest biopharma IPO in 2017.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org